Hemophilia A inhibitors prevalence and risk factors: A Review Article | ||
| Zagazig University Medical Journal | ||
| Article 34, Volume 30, Issue 8.1, November 2024, Pages 4104-4108 PDF (1.01 M) | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/zumj.2024.265639.3139 | ||
| Authors | ||
| Abdel Razek El-Sheikh1; Marwa Zakaria2; nada kamal soliman* 3; Laila M Sherief4 | ||
| 1Pediatrics Department, Faculty of Medicine, Zagazig University, Egypt | ||
| 2pediatric department, faculity of medicine, zagazig university | ||
| 3pediatric department, faculty of medicine, zagazig university, egypt | ||
| 4Pediatrics Department, faculty of medicine, zagazig university, egypt | ||
| Abstract | ||
| Background: Hemophilia A is a bleeding disorder results from genetic mutation in the coagulation factor synthesis process, which is critical for maintaining hemostasis. Hemophilia A, an X-linked disorder that affects males at a prevalence of 1:5000–10,00000, is the most frequent type and is caused by a deficiency of factor VIII (FVIII). Replacement therapy for FVIII is still the cornerstone for treatment of hemophilia A. The main side effect of replacement therapy is the development of antibodies, which significantly reduces the therapeutic effectiveness by blocking FVIII activity. FVIII Inhibitors might be high or low titer. Risk factors, both genetic and non-genetic, influence the development of FVIII inhibitors. The types, prevalence, and risk factors of FVIII inhibitors are summarized in the current review. Conclusion: Hemophilia A is an inherited disease due to decrease in FVIII synthesis. Accordingly, normal homeostasis is affected leading to bleeding according to the level FVIII and the site of bleeding. Meanwhile, treatment of hemophilia A by replacement factor may lead to inhibitor formation which is a major challenge. | ||
| Keywords | ||
| Hemophilia; Inhibitors; Risk factors | ||
|
Statistics Article View: 5,359 PDF Download: 174 |
||
